Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 15180 publications
X-BODY BioSciences, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of X-BODY BioSciences, Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the X-BODY BioSciences, Inc.’s pipeline products Reasons to ...

Dec, 2014 30 pages
Vaccibody AS - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

Vaccibody AS - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Vaccibody AS - Product Pipeline Review - 2014’, provides an overview of the Vaccibody AS’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental ...

Dec, 2014 27 pages
Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... . Scope The report provides brief overview of Tonix Pharmaceuticals Holding Corp. including business description, key information and facts, and its ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Tonix Pharmaceuticals Holding Corp.’s pipeline products ...

Dec, 2014 32 pages
Tesaro, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Tesaro, Inc.’s pipeline products ... drug targets and therapeutic classes in the Tesaro, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 42 pages
Syntiron LLC - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Syntiron LLC’s pipeline products ... drug targets and therapeutic classes in the Syntiron LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 22 pages
Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Shanghai Pharmaceutical Co., Ltd.’s pipeline products Reasons ...

Dec, 2014 29 pages
Sensorion S.A.S. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

Sensorion S.A.S. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Sensorion S.A.S. - Product Pipeline Review - 2014’, provides an overview of the Sensorion S.A.S.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...

Dec, 2014 19 pages
Sagene Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Sagene Pharmaceuticals, Inc.’s pipeline products Reasons ... Assess the growth potential of Sagene Pharmaceuticals, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the ...

Dec, 2014 19 pages
RFS Pharma, LLC - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the RFS Pharma, LLC’s pipeline products Reasons ...

Dec, 2014 27 pages
Planet Biotechnology Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Planet Biotechnology Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Planet Biotechnology Inc.’s pipeline products Reasons to ...

Dec, 2014 25 pages
PhaseRx, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the PhaseRx, Inc.’s pipeline products ... drug targets and therapeutic classes in the PhaseRx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 21 pages
PCI Biotech AS - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of PCI Biotech AS’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the PCI Biotech AS’s pipeline products ...

Dec, 2014 31 pages
Parion Sciences, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Parion Sciences, Inc.’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the Parion Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce ...

Dec, 2014 27 pages
Nuevolution A/S - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

Nuevolution A/S - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Nuevolution A/S - Product Pipeline Review - 2014’, provides an overview of the Nuevolution A/S’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...

Dec, 2014 25 pages
NovoBiotic Pharmaceuticals, LLC - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the NovoBiotic Pharmaceuticals, LLC’s pipeline products Reasons ...

Dec, 2014 19 pages
Neurotez, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Neurotez, Inc.’s pipeline products ... drug targets and therapeutic classes in the Neurotez, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 21 pages
Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... disease. Scope The report provides brief overview of Meiji Seika Pharma Co., Ltd. including business description, key information and facts, and its ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Meiji Seika Pharma Co., Ltd.’s pipeline products ...

Dec, 2014 46 pages
Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Kolltan Pharmaceuticals, Inc.’s pipeline products Reasons to ...

Dec, 2014 32 pages
Kadmon Corporation, LLC - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Kadmon Corporation, LLC’s human therapeutic ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Kadmon Corporation, LLC’s pipeline products Reasons ...

Dec, 2014 44 pages
ImmuVen, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the ImmuVen, Inc.’s pipeline products ... drug targets and therapeutic classes in the ImmuVen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 20 pages
Griffin Discoveries BV - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... and its locations and subsidiaries The report reviews current pipeline of Griffin Discoveries BV’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Griffin Discoveries BV’s pipeline products ...

Dec, 2014 20 pages
Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... disease. Scope The report provides brief overview of Eagle Pharmaceuticals Inc. including business description, key information and facts, and its ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Eagle Pharmaceuticals Inc.’s pipeline products Reasons ...

Dec, 2014 26 pages
Cellectis S.A. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

Cellectis S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Cellectis S.A. - Product Pipeline Review - 2014’, provides an overview of the Cellectis S.A.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...

Dec, 2014 41 pages
Catalyst Biosciences, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Catalyst Biosciences, Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Catalyst Biosciences, Inc.’s pipeline products Reasons ...

Dec, 2014 25 pages
aTyr Pharma, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the aTyr Pharma, Inc.’s pipeline products Reasons ...

Dec, 2014 21 pages
AtheroNova Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the AtheroNova Inc.’s pipeline products ... drug targets and therapeutic classes in the AtheroNova Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Dec, 2014 30 pages
American Gene Technologies International Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the American Gene Technologies International Inc.’s pipeline ...

Dec, 2014 24 pages
Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 US$ 1,350.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Alitair Pharmaceuticals, Inc.’s pipeline products Reasons to ...

Dec, 2014 26 pages
2014 Market Research Report on Global Vitamin K3 Industry US$ 2,600.00

2014 Market Research Report on Global Vitamin K3 Industry is a professional and depth research report on Global Vitamin K3 industry For overview analysis, the report ... , cost, price, profit, production value, and gross margin for these markets are also included. For technical data and manufacturing plants ...

Dec, 2014 180 pages
Vaginitis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Vaginitis Global Clinical Trials Review, H2, 2014' provides data on the Vaginitis clinical trial scenario. This ... type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / ...

Dec, 2014 68 pages
Trichuriasis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Trichuriasis Global Clinical Trials Review, H2, 2014' provides data on the Trichuriasis clinical trial scenario. This ... type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Dec, 2014 56 pages
Respiratory Syncytial Virus (RSV) Infections Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Respiratory Syncytial Virus (RSV) Infections clinical trial scenario. This report provides elemental information and ... and top five national contributions in each Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor ...

Nov, 2014 105 pages
Pyelonephritis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Pyelonephritis Global Clinical Trials Review, H2, 2014' provides data on the Pyelonephritis clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Dec, 2014 88 pages
Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Onychomycosis (Tinea Unguium) clinical trial scenario. This report provides elemental information and data relating ... and top five national contributions in each Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor ...

Nov, 2014 87 pages
Malignant Pleural Effusion Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Malignant Pleural Effusion clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Nov, 2014 71 pages
Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2014' provides data on the Lymphangioleiomyomatosis clinical trial scenario. This report provides elemental information and data ...

Nov, 2014 73 pages
Lyme Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Lyme Disease. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Nov, 2014 59 pages
Kaposi's Sarcoma Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Kaposi’s Sarcoma. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Dec, 2014 79 pages
Cystic Fibrosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Cystic Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Nov, 2014 108 pages
Bronchiolitis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Bronchiolitis Global Clinical Trials Review, H2, 2014' provides data on the Bronchiolitis clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Nov, 2014 71 pages
Brazil Pharmaceutical Market Outlook 2018 US$ 1,000.00

... ’s overall healthcare services and facilities. In our latest research study “Brazil Pharmaceutical Market Outlook 2018”, RNCOS’ analysts have identified the ... , which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018. RNCOS’ analysis shows that the Over-the-Counter drug ...

Dec, 2014 90 pages
Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin US$ 1,500.00

The industry research publication titled ‘Asia Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin’ presents a comprehensive analysis of ... . The world’s largest diabetic population resides in Asia Pacific due to which the demand for insulin is on a constant rise. Japan, China and ...

Sep, 2014 146 pages
Rodos BioTarget GmbH - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Rodos BioTarget GmbH’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the Rodos BioTarget GmbH’s R&D portfolio and develop key strategic initiatives to reinforce ...

Dec, 2014 18 pages
RAPID Pharmaceuticals AG - Product Pipeline Review - 2014 US$ 1,500.00

... The report reviews current pipeline of RAPID Pharmaceuticals AG’s human therapeutic division and enlists all their major and minor projects The report ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the RAPID Pharmaceuticals AG’s pipeline products ...

Dec, 2014 22 pages
Piramal Enterprises Limited - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Piramal Enterprises Limited’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Piramal Enterprises Limited’s pipeline products Reasons ...

Dec, 2014 44 pages
Panmira Pharmaceuticals, LLC. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Panmira Pharmaceuticals, LLC.’s pipeline products Reasons to ...

Dec, 2014 22 pages
OncoSec Medical Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the OncoSec Medical Inc.’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the OncoSec Medical Inc.’s R&D portfolio and develop key strategic initiatives to reinforce ...

Dec, 2014 29 pages
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H2 2014 US$ 2,000.00

... III) (Sanfilippo Syndrome) - Pipeline Review, H2 2014’, provides an overview of the Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome), ...

Dec, 2014 59 pages
Kite Pharma, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Kite Pharma, Inc.’s pipeline products Reasons ...

Dec, 2014 31 pages
Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Grupo Ferrer Internacional, S.A.’s pipeline products Reasons ...

Dec, 2014 38 pages
1 2 3 4 5 >
Skip to top